Americas Interventional Radiology Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Americas Interventional Radiology Market Trends and Insights

Increasing Burden of Chronic Cardiovascular & Oncological Diseases

Hypertension prevalence is projected to climb from 51.2% to 61.0% by 2050, and diabetes from 16.3% to 26.8%, adding a steady pipeline of complex cases amenable to catheter-based interventions. The aging population magnifies disease incidence, while patient preference for shorter recovery dovetails with hospital efforts to lower length of stay. Together these factors increase case volumes for peripheral angioplasty, renal denervation, and tumor embolization. Consequently, America’s interventional radiology market benefits from structural tailwinds that consistently replenish procedural demand.

Technological Advances in IR Imaging (Photon-Counting CT, AI, AR)

Photon-counting detector CT enables higher spatial resolution and intrinsic spectral separation, which improves tissue contrast while cutting radiation dose compared to energy-integrating systems, thereby elevating diagnostic certainty in complex vascular interventions. Clinical studies show vessel-sharpness ratings of 134.7 HU/mm versus 100.9 HU/mm on conventional scanners, facilitating precise device deployment in coronary and neurovascular procedures. AI-enabled robotic platforms overlay real-time trajectory guidance, automate wire manipulation, and reduce fluoroscopy time by up to 56%, which eases radiation safety concerns for staff and patients. Augmented-reality head-mounted displays further shorten learning curves for complex ablation or embolization. Early adopters realize competitive gains through lower complication rates and higher throughput, reinforcing the technological arms race within America’s interventional radiology market.

Rapid Expansion of Office-Based Labs (OBLs) & ASCs in the Americas

More than 700 OBLs were operational in the United States in 2021, and their number is projected to grow at 7.5% annually through 2030 on the strength of bundled payments and patient preference for community-based care. Medicare data confirm that 6,100 ASCs handled 3.3 million beneficiaries in 2022, with procedure volume per beneficiary up 2.8% year on year. Outpatient sites typically deliver 35% lower episode costs than hospital outpatient departments, creating strong payer incentives for migration of angioplasty, uterine fibroid embolization, and port placements. The resulting redistribution of caseload supports double-digit equipment sales into small footprints that rely on compact C-arms and ultrasound guidance. These dynamics underpin near-term revenue growth in America’s interventional radiology market.

Shift to Value-Based Care Favoring Minimally-Invasive IR Over Surgery

The Centers for Medicare & Medicaid Services approved transitional pass-through payment for Medtronic’s Symplicity Spyral renal denervation catheter effective January 2025, signifying regulatory endorsement for novel catheter therapies that reduce downstream hospitalization costs. The 2025 CPT update introduced 270 new codes, including MRI-guided ablation and complex embolization bundles that streamline billing and raise professional fees for image-guided care. Health systems see shorter length of stay and fewer complications with percutaneous options, which increases alignment between clinical outcomes and payment quality metrics. Consequently, procedural referrals tilt toward interventional suites, stimulating durable adoption across vascular, oncologic, and neurologic lines within America’s interventional radiology market.

High Capital Cost of IR Suites & Advanced Imaging Modalities

Photon-counting CT scanners, robotic C-arms, and hybrid operating rooms each require outlays above USD 2 million, with entire suite buildouts reaching USD 5 million, which strains hospital balance sheets already operating at 1.2% median operating margins. Annual service contracts consume 15 – 20% of purchase price, while software upgrades add incremental costs that small systems struggle to absorb. Latin American hospitals face 30 – 40% price premiums driven by import tariffs and currency volatility, raising barriers to adoption. Deferred-payment leasing and refurbished equipment programs are expanding, yet premium financing charges dilute investment returns. As a result, America’s interventional radiology market encounters localized slowdowns where capital intensity outweighs clinical demand.

Shortage of Trained Interventional Radiologists in Latin America

Only 15.5% of U.S. counties have an interventional radiologist, and 31.2% of the population lacks direct access to interventional expertise, illustrating the depth of workforce scarcity. Latin American training programs face limited fellowship slots, outdated curricula, and funding gaps, thereby prolonging skill deficits despite growing disease burden. The practicing IR cohort in the United States shrank 7% from 2013 to 2020, even as evaluation and management claims climbed 35%, indicating widening imbalances between demand and supply. Workforce expansion lags six years behind fellowship enrollment because of training duration, locking in shortages that constrain procedural capacity across underserved geographies within America’s interventional radiology market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product: Consumables Drive Revenue While Equipment Spurs Innovation

Consumables and devices accounted for 52.22% of America’s interventional radiology market share in 2025, buoyed by high procedure frequency and single-use mandates that accelerate replacement cycles. Stents, catheters, guidewires, and embolic agents dominate hospital procurement lists because multifaceted procedures require multiple SKUs per case. The stent subsegment gained further traction after Abbott secured FDA clearance for its dissolving Esprit BTK scaffold for below-the-knee disease, a milestone that reshapes peripheral revascularization options. Biopsy and thrombectomy kits also expand as stroke and oncology protocols emphasize early intervention.

Imaging equipment represents the fastest-growing category at a 6.73% CAGR through 2031 as facilities upgrade to photon-counting CT, self-driving C-arms, and AI-integrated MRI that mitigate radiologist shortages and enhance workflow. Hospitals leverage financing partnerships to acquire comprehensive platforms that bundle scanners, software, and analytics services, improving lifetime value. AI-rich ultrasound systems are penetrating office-based labs due to portability and rapid learning curves, while angiography suites adopt radiation-free light-based navigation that can slash fluoroscopy exposure by over half. These trends drive a premium replacement cycle that anchors long-term expansion in America’s interventional radiology market.

By Application: Cardiology Commands the Present, Oncology Fuels the Future

Cardiology dominated America’s interventional radiology market size with 38.27% in 2025, supported by entrenched reimbursement pathways and decades of evidence favoring catheter-based treatments over open surgery for coronary and structural heart disease. Pulsed field ablation systems from Medtronic, Boston Scientific, and Abbott have democratized atrial fibrillation treatment by shortening procedure time and reducing collateral tissue injury, which stimulates incremental device sales. Hypertension trials using renal denervation catheters show sustained blood pressure reduction, adding a new patient pool for interventional treatment.

Oncology interventions are expanding at 7.22% CAGR, the fastest among clinical segments, as image-guided tumor ablation, chemoembolization, and selective internal radiation therapy align with precision medicine strategies that seek localized high-dose delivery with minimal systemic toxicity. Theranostic workflows that integrate diagnostic imaging and localized therapy elevate scanner utilization and consumable turnover, fostering a virtuous cycle for vendors. The rising incidence of hepatocellular carcinoma and lung metastases, combined with improved survival, ensures sustained procedural demand for ablation needles, microspheres, and drug-eluting beads.

By End User: Hospitals Anchor Complexity, Specialized Centers Accelerate Volume

Hospitals retained a 63.02% share of America’s interventional radiology market in 2025, justified by their ability to aggregate multidisciplinary expertise, intensive care backup, and advanced imaging suites necessary for high-risk cases. Complex stroke thrombectomies, large-vessel aneurysm repairs, and pediatric interventions remain hospital mainstays. Moreover, academic centers lead early adoption of photon-counting CT and robotic angiography, driving demand for vendor-bundled service contracts.

Contract development and manufacturing organizations, office-based labs, and ambulatory surgical centers are registering the highest growth at 7.76% CAGR because they capture routine vascular access, dialysis interventions, and pain management procedures under cost-efficient settings. These sites rely on compact fluoroscopy and ultrasound platforms and favor disposable kits that streamline turnover. Specialty clinics focusing on endovascular limb salvage and uterine fibroid embolization thrive on targeted marketing and bundled payment contracts that reward high patient satisfaction. This multisite delivery ecosystem diversifies revenue streams and underpins the long-run scalability of America’s interventional radiology market.

Geography Analysis

North America generated 92.90% of total revenue in 2025 and is forecast to expand at 8.45% CAGR through 2031 as Medicare Advantage enrollment rises and CPT code revisions improve practice economics. The United States leads photon-counting CT installations and has already performed first-in-human procedures with AI-guided transcatheter valves, reinforcing technological leadership. Canada benefits from federal investments in health-system modernization that include dedicated funding for ambulatory stroke services and PET/CT expansion.

South America remains under-penetrated yet strategically important. Brazil accelerated ANVISA approvals by recognizing FDA and Health Canada clearances, which cut regulatory timelines to 6-9 months for qualified devices, supporting faster market entry for stents, ablation systems, and catheter technologies. Currency headwinds and import taxes still inflate equipment costs, but vendor-financed leasing and refurbished platforms help mitigate barriers. Argentina’s economic volatility tempers near-term purchasing power; however, rising private-sector investments in vascular care highlight latent demand for cost-effective, minimally-invasive solutions.

The remainder of South America faces infrastructure gaps and workforce shortages but demonstrates strong appetite for professional education. Cross-border training programs reveal that over 80% of Latin American radiologists prioritize interventional skill acquisition, pointing to future volume growth once capital and regulatory hurdles ease. International equipment vendors with turnkey training, financing, and service bundles are likely to gain early footholds as socioeconomic conditions stabilize, enabling broader expansion of America’s interventional radiology market.

Regulatory Landscape

In the United States, interventional radiology equipment, software, and disposable devices are regulated by the US Food and Drug Administration (FDA) under a risk-based framework, with device quality oversight updated through the Quality Management System Regulation (QMSR) that took effect on February 2, 2026 and aligned 21 CFR Part 820 more closely with ISO 13485:2016. The FDA also transitioned to the Inspection of Medical Device Manufacturers Compliance Program (7382.850) on the same date, which updated inspection expectations for manufacturers supplying IR suites, imaging platforms, and catheter-based tools.

Regulatory clarity is also expanding for software-enabled IR workflows. On June 17, 2026, the FDA codified radiological machine learning-based quantitative imaging software with predetermined change control plans as Class II under 21 CFR 892.2055, supporting more structured update pathways for AI features embedded in interventional imaging. For procedure-specific devices, FDA special controls guidance (for example, vascular and neurovascular embolization devices) continues to shape test requirements, labeling, and performance evidence used by manufacturers active across the Americas.

Value Chain Analysis

The value chain covers upstream components and materials (detectors, x-ray tubes, power and vacuum products, electronics, polymers, and nitinol-based structures), device and system design, manufacturing and sterilization (for single-use catheters, guidewires, embolics, and thrombectomy tools), regulatory and quality compliance, and downstream commercialization through direct sales and distributor networks to hospitals, OBLs/ASCs, and specialty clinics. Capital equipment economics place service, software, and lifecycle management alongside hardware as core profit pools, particularly as facilities weigh suite buildouts against operational constraints.

Major OEMs increasingly influence midstream integration and installed-base monetization. Siemens Healthineers has organized technology centers (including mechatronic products, medical electronics, and power and vacuum products) that support multiple segments, reinforcing vertical integration of critical imaging subassemblies used in angiography and interventional systems. On the demand side, GE HealthCare has emphasized upgrade pathways for existing interventional suites, shifting the channel mix toward retrofit software and workflow modules rather than full system replacement. FUJIFILM, in parallel, is pushing hospital-wide data integration strategies that connect imaging and clinical IT across departments, pulling PACS/enterprise imaging, interoperability, and workflow software further into the IR delivery chain.

Market Opportunities and Future Outlook

A central opportunity is monetizing the installed base of interventional suites through modernization rather than replacement, especially where hybrid rooms and advanced imaging modalities carry high capital costs. In 2026, GE HealthCare introduced Allia platform upgrade pathways for legacy Innova and Discovery systems in the United States, creating a defined route for providers to add newer reconstruction and workflow tools while keeping existing infrastructure in place. This supports vendors selling modular upgrades, managed service contracts, and financing bundles aligned to hospital and outpatient refresh cycles that prioritize uptime.

Another opportunity is workflow-centric integration across imaging, therapy, and software, particularly where AI and planning tools reduce staff burden and standardize complex procedures. Siemens Healthineers has organized assets under a Precision Therapy segment that combines Varian and Advanced Therapies with Ultrasound, reflecting a portfolio pull toward image-guided treatment and AI-powered applications that can span oncology, vascular, and neuro workflows. The FDA action on June 17, 2026 to codify certain ML-based quantitative imaging software (with predetermined change control plans) as Class II strengthens the commercialization pathway for AI features that require iterative updates, supporting partnerships and co-marketing models such as treatment-planning integrations around angiography platforms. In Latin America, workforce and capital constraints create whitespace for turnkey offerings that combine equipment access, clinical education, and enterprise imaging integration, particularly as interventional procedures shift toward outpatient footprints that support compact, software-rich systems.